Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors.
Moran Gvili PerelmanRafael Y BrzezinskiBarliz WaissengrinYasmin LeshemOr BainhorenTammi Arbel RubinsteinMaxim PerelmanZach RozenbaumOfer HavakukYan TopilskyShmuel BanaiIdo WolfMichal Laufer-PerlPublished in: Cardio-oncology (London, England) (2024)
SGLT2i therapy was associated with a lower all-cause mortality rate in patients diagnosed with cancer and DM2 and treated with ICIs. Further studies are needed to understand the mechanism and evaluate its benefit on cardiotoxicity.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- papillary thyroid
- prognostic factors
- stem cells
- squamous cell carcinoma
- patient reported outcomes
- adipose tissue
- metabolic syndrome
- young adults
- squamous cell
- mesenchymal stem cells
- bone marrow
- lymph node metastasis